A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

Immunisation with nirsevimab reduced bronchiolitis-related hospitalisations among infants younger than 3 months who visited the emergency department (ED), according to a new study. Nirsevimab also ...

Nirsevimab is a long-acting monoclonal antibody designed to provide passive immunity against RSV in infants and young children. The Advisory Committee on Immunization Practices (ACIP) recommends ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

From next Monday, 17 March, free immunisation from respiratory syncytial virus (RSV) will be available to all newborn babies.